View in EDS

Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.

Saved in:
Bibliographic Details
Title: Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Authors: Spratt DE; Radiation Oncology, UH Seidman Cancer Center/Case Western Reserve University, Cleveland, OH 441062, USA., Dorff T; Medical Oncology, City of Hope, Duarte, CA 910103, USA., McKay RR; Medical Oncology, UC San Diego, La Jolla, CA 920374, USA., Lowentritt BH; Urology, Chesapeake Urology, Towson, MD 212045, USA., Fallick M; Myovant Sciences Inc., Brisbane, CA 940056, USA., Gatoulis SC; Pfizer, New York, NY 100177, USA., Flanders SC; Myovant Sciences Inc., Brisbane, CA & Sumitomo Pharma America Inc., Marlborough, MA 017528, USA., Ross AE; Urology, Northwestern Medicine, Chicago, IL 60611, USA.
Source: Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 727-738. Date of Electronic Publication: 2024 Mar 15.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38488039
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Spratt+DE%22">Spratt DE</searchLink>; Radiation Oncology, UH Seidman Cancer Center/Case Western Reserve University, Cleveland, OH 441062, USA.<br /><searchLink fieldCode="AU" term="%22Dorff+T%22">Dorff T</searchLink>; Medical Oncology, City of Hope, Duarte, CA 910103, USA.<br /><searchLink fieldCode="AU" term="%22McKay+RR%22">McKay RR</searchLink>; Medical Oncology, UC San Diego, La Jolla, CA 920374, USA.<br /><searchLink fieldCode="AU" term="%22Lowentritt+BH%22">Lowentritt BH</searchLink>; Urology, Chesapeake Urology, Towson, MD 212045, USA.<br /><searchLink fieldCode="AU" term="%22Fallick+M%22">Fallick M</searchLink>; Myovant Sciences Inc., Brisbane, CA 940056, USA.<br /><searchLink fieldCode="AU" term="%22Gatoulis+SC%22">Gatoulis SC</searchLink>; Pfizer, New York, NY 100177, USA.<br /><searchLink fieldCode="AU" term="%22Flanders+SC%22">Flanders SC</searchLink>; Myovant Sciences Inc., Brisbane, CA & Sumitomo Pharma America Inc., Marlborough, MA 017528, USA.<br /><searchLink fieldCode="AU" term="%22Ross+AE%22">Ross AE</searchLink>; Urology, Northwestern Medicine, Chicago, IL 60611, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 727-738. <i>Date of Electronic Publication: </i>2024 Mar 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial Protocol
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38488039
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/fon-2023-0748
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 727
    Titles:
      – TitleFull: Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Spratt DE
      – PersonEntity:
          Name:
            NameFull: Dorff T
      – PersonEntity:
          Name:
            NameFull: McKay RR
      – PersonEntity:
          Name:
            NameFull: Lowentritt BH
      – PersonEntity:
          Name:
            NameFull: Fallick M
      – PersonEntity:
          Name:
            NameFull: Gatoulis SC
      – PersonEntity:
          Name:
            NameFull: Flanders SC
      – PersonEntity:
          Name:
            NameFull: Ross AE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1